Webinar: Novel Drug Conjugates and Clinical Success

Novel Drug Conjugates and Clinical Success: An In-Depth Analysis of Emerging ADCs

As the landscape of targeted cancer therapies continues to evolve, novel drug conjugates are emerging as a transformative force in the ADC space. This webinar delved into the cutting-edge advancements that are shaping the future of ADCs, and focused on how these innovative conjugates are poised to revolutionize cancer treatment and beyond.

Emerging Novel ADC Webinar

This webinar provides an in-depth analysis of the most promising developments in novel drug conjugates, including the exploration of diverse payloads and targets that are pushing the boundaries of precision medicine. Examine the rise of Bispecific ADCs (BsADCs) and antibody degrader conjugates, which offer new mechanisms of action and improved specificity, paving the way for safer and more effective therapies.

View Webinar

Our Experts

Yu-Shin Hsu

House Speaker

Cell Therapy Lead Research Analyst

Beacon

Callum Angus

House Speaker

Senior Market Analyst

Hanson Wade Intelligence

Jake Morris

Moderator

Senior Account Manager

Beacon

You May Also Be Interested In…

Webinar date: 14/05/2025

Navigating Payload Innovation and Toxicity Trends in ADC Development

AACR 2025: ADC Pre-Conference Planner

Access Report

ADC Landscape Review

Access Review

View All

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more